logo
World's first silicon-based quantum computer is small enough to plug into a regular power socket

World's first silicon-based quantum computer is small enough to plug into a regular power socket

Business Mayor07-05-2025

A startup has launched the first quantum device in the world that blends the potential of quantum computing with the convenience and integration of traditional high-performance computing (HPC).
Equal1 representatives unveiled Bell-1 on March 16 — a new six- qubit machine that can fit seamlessly into existing HPC environments like data centers, company representatives said in a statement .
The machine tips the scale at slightly more than 440 pounds (200 kilograms) but it's rack-mountable — meaning it can be mounted onto a physical rack in a data center — and it's roughly the same size as existing graphics processing unit (GPU) servers.
Unlike other quantum computers, the Bell-1 doesn't require specialized infrastructure to deploy, and it doesn't need additional equipment to be cooled to near-absolute zero.
Related: China achieves quantum supremacy claim with new chip 1 quadrillion times faster than the most powerful supercomputers
That's because it boasts its own self-contained, closed-cycle cryo cooling unit, which enables the system to operate at a remarkable 0.3 kelvin, or minus 459.13 degrees Fahrenheit (minus 272.85 degrees Celsius).
The machine makes use of the latest semiconductor fabrication techniques as well as purified silicon , which allows for a high level of control and long coherence times (a qubit's ability to exist in multiple states simultaneously, which is crucial for quantum algorithms and computations).
Get the world's most fascinating discoveries delivered straight to your inbox.
Rack-mountable quantum computing
The Bell-1's qubits are silicon-based, meaning they're smaller than conventional qubits, and the chip at the heart of the machine incorporates quantum processor units (QPUs) with Arm CPUs — traditional processors known for their small size and efficiency — and neural processing units (NPUs) — specialized processors for accelerating machine learning and artificial intelligence (AI).
Incorporating all these elements onto a single chip eliminates the complex orchestration that would otherwise be necessary between classical and quantum computing elements. As long as you've got the space in a rack, all it requires is a standard electrical outlet: plug it in and it's ready to work, Equal1 representatives said.
(Image credit: Fergal Phillips)
The company's chip, called the UnityQ 6-Qubit Quantum Processing System, utilizes spin qubits, in contrast to many quantum computing platforms that rely on either trapped-ion or superconducting qubits. Silicon-based spin qubits are compact, leading to potentially higher qubit density, and could leverage existing semiconductor fabrication techniques, meaning more scalability.
The chip fitted into the Bell-1 also incorporates error correction, control and readout, while taking advantage of existing semiconductor infrastructure for reliability and scalability.
Although this first generation of the chip includes six qubits, the company wants to make more powerful versions with a higher qubit count. The Bell-1 is also future-proof in that early adopters can upgrade existing systems as new models are rolled out, rather than replacing them with new machines, company representatives added.
The Bell-1 builds on advances first published by the company in December 2024, which established new peak performance marks for silicon qubit arrays as well as quantum controller chips.
These included the world's highest recorded single-qubit and two-qubit gate fidelity (meaning fewer errors) and gate speed (meaning faster operations). The platform also utilizes a specialized, AI-powered error correction system developed in partnership with Arm.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition
MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

Miami Herald

time42 minutes ago

  • Miami Herald

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss MIAMI, FLORIDA / ACCESS Newswire / June 30, 2025 / MIRA (NASDAQ:MIRA) today announced new animal study results from SKNY-1, a next-generation oral therapeutic under definitive agreement for acquisition. In a zebrafish model that mimics human obesity and craving behaviors, SKNY-1 demonstrated weight loss, suppression of appetite and craving for high-calorie diets, and reversal of nicotine-seeking behavior-all achieved within six days of oral treatment. SKNY-1 is being developed as an oral alternative to GLP-1 injectables, which are often limited by nausea, GI discomfort, injection reaction, and growing concerns around muscle loss. Unlike GLP-1s, which reduce both fat and lean mass, SKNY-1 demonstrated significant weight loss with preserved muscle. It was specifically designed to minimize engagement with central nervous system pathways implicated in the psychiatric side effects observed in some smoking cessation therapies and first-generation CB1-targeting weight-loss drugs. The data support SKNY-1's potential as a differentiated oral therapy addressing two of the world's leading causes of preventable death. The study was conducted in an obesity and craving model in Ob42 Strain-mc4r (G894C) mutated zebrafish following six days of oral treatment with two doses of SKNY-1 and was compared to normal controls. Key Results Weight Loss and Muscle Preservation:SKNY-1 reduced body weight by approximately 30% after just six days of oral treatment. Treated animals ended up weighing about 10% less than healthy controls. Importantly, this weight loss was not accompanied by muscle density changes-suggesting SKNY-1 helps burn fat while preserving lean body mass. Metabolic Activity and Ventilation Rate:Treated animals showed an increase in breathing rate, which is a reliable signal that their metabolism was speeding up. This aligns with the observed weight loss and suggests that SKNY-1 helps the body burn more energy. Liver and Lipid Profile Improvements:In untreated obese animals, fat buildup in the liver was about 50% higher than normal. SKNY-1 reversed this buildup, bringing liver fat back to healthy levels. At the same time, cholesterol levels-including LDL ('bad' cholesterol) and HDL ('good' cholesterol)-also returned to normal, without affecting fat levels in the blood. This points to improved fat processing without disrupting the body's overall metabolic balance. Appetite, Craving, and Compulsive Eating:Obese animals were eating 2-3 times more high-calorie food than normal. SKNY-1 dose-dependently reduced this behavior-high-dose animals ate less than healthy controls. The drug also made the animals less likely to pursue food in stressful environments and reduced obsessive food-seeking in tests designed to measure craving. Nicotine Craving and Compulsivity:SKNY-1 significantly reduced the desire to seek out and consume nicotine. Treated animals were less willing to pursue nicotine even in stressful conditions, and they no longer showed a preference for environments linked to nicotine rewards. At the high dose, their behavior matched that of healthy animals with no nicotine craving. Neurohormonal Balance:Obese animals had extremely high levels of leptin (a hunger-regulating hormone) and unusually low levels of ghrelin (the 'hunger signal'). This imbalance often leads to constant hunger and poor appetite control. SKNY-1 normalized both hormones, improving the body's ability to regulate hunger and energy use. Brain Dopamine Regulation:Obese animals had too much dopamine in the brain, likely tied to increased reward and cravings. SKNY-1 reduced these dopamine levels-but only at the lower dose. The high dose did not affect dopamine, suggesting the drug can reduce craving without overstimulating the brain. "Within just six days, we saw robust behavioral, hormonal and metabolic changes, including weight loss, improved fat metabolism, and reversal of craving-like behaviors," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "These results highlight SKNY-1's potential to address both obesity and nicotine addiction through unique and safe pathways." A Differentiated Approach to Two Major Markets Current weight-loss therapies like semaglutide and tirzepatide are effective but limited by gastrointestinal side effects, injectable administration, and loss of lean mass. Smoking cessation treatments such as varenicline and bupropion carry psychiatric warnings and offer modest long-term quit rates. SKNY-1 was designed to overcome these limitations. It selectively modulates CB1 receptors by blocking β-arrestin signaling-associated with cravings and compulsive behavior-while preserving G-protein signaling, which supports emotional and cognitive stability. The compound also activates CB2 receptors and mildly inhibits MAO-B without affecting MAO-A, supporting a favorable safety and tolerability profile. "These results position SKNY-1 as a potentially disruptive oral treatment," said Erez Aminov, CEO of MIRA. "Its ability to reduce body mass, suppress cravings, and preserve muscle-all through oral administration-makes it a compelling therapeutic candidate as we move toward closing the acquisition and preparing for IND-enabling studies." The Company believes these findings further support the advancement of SKNY-1 toward Investigational New Drug (IND)-enabling studies. With obesity and smoking representing two of the leading causes of preventable death-and a combined global market opportunity exceeding $200 billion-MIRA intends to prioritize SKNY-1 as a potential cornerstone asset pending completion of the acquisition of SKNY Pharmaceuticals, Inc. About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as anxiety, cognitive decline, neuropathic pain, obesity, and addiction. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals

5 Revealing Analyst Questions From 1-800-FLOWERS's Q1 Earnings Call
5 Revealing Analyst Questions From 1-800-FLOWERS's Q1 Earnings Call

Yahoo

timean hour ago

  • Yahoo

5 Revealing Analyst Questions From 1-800-FLOWERS's Q1 Earnings Call

1-800-FLOWERS faced a difficult first quarter, as the market responded sharply to results that missed Wall Street's expectations. Management attributed the shortfall to both external and internal factors, including declining consumer sentiment, increased tariffs, and expensive digital marketing channels that failed to yield expected returns. CEO Jim McCann was notably self-critical, describing the company's order management system rollout as a 'colossal screw-up' that impacted sales and customer satisfaction, particularly in the Harry & David brand. The leadership team also acknowledged the loss of lower-income customers and a promotional market environment as key contributors to the quarter's underperformance. Is now the time to buy FLWS? Find out in our full research report (it's free). Revenue: $331.5 million vs analyst estimates of $364.2 million (12.6% year-on-year decline, 9% miss) Adjusted EPS: -$0.71 vs analyst estimates of -$0.34 (significant miss) Adjusted EBITDA: -$34.92 million vs analyst estimates of -$12.43 million (-10.5% margin, significant miss) Operating Margin: -16.7%, down from -6.4% in the same quarter last year Market Capitalization: $326.1 million While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Anthony Lebiedzinski (Sidoti and Company) asked about the impact of holiday timing and the Easter shift on sales. CEO Jim McCann and CFO James Langrock confirmed that holiday placement helped, but everyday business remained soft, and the Easter shift materially affected year-over-year comparisons. Lebiedzinski (Sidoti and Company) questioned the financial and operational impact of the order management system issues. McCann called the implementation a 'colossal screw-up' and Langrock estimated at least $20 million in lost sales and $11 million in incremental costs over two quarters. Lebiedzinski (Sidoti and Company) sought details on the Celebrations Wave timeline, asking what could be achieved in the first year. Management outlined near-term steps including new app capabilities, expanded relationship management tools, and AI-powered personalization for customer engagement. Michael Kupinski (NOBLE Capital Markets) asked whether revenue weakness was concentrated among higher or lower-income customers. President Tom Hartnett stated the biggest declines were among lower-income consumers, while higher-end customers continued to spend on premium items. Doug Lane (Water Tower Research) inquired about the decision to exit retail during COVID and prospects for returning to physical stores. McCann admitted the closure was a mistake and discussed plans for further holiday pop-ups and select permanent store locations based on recent positive results. In the coming quarters, the StockStory team will watch for (1) measurable reductions in customer acquisition costs from the Celebrations Wave ecosystem, (2) progress on resolving order management and system implementation issues, and (3) stabilization or recovery in everyday gifting demand outside of major holidays. Additional attention will be paid to early traction from the company's AI-driven personalization features and any material impacts from changes in tariff policy or consumer sentiment. 1-800-FLOWERS currently trades at $5.13, down from $5.80 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio

Northstar Announces Receipt of Letter of Interest on Potential Funding for up to Four United States Asphalt Shingle Reprocessing Facilities
Northstar Announces Receipt of Letter of Interest on Potential Funding for up to Four United States Asphalt Shingle Reprocessing Facilities

Yahoo

time2 hours ago

  • Yahoo

Northstar Announces Receipt of Letter of Interest on Potential Funding for up to Four United States Asphalt Shingle Reprocessing Facilities

CALGARY, AB, June 30, 2025 /CNW/ - Northstar Clean Technologies Inc. (TSXV: ROOF) (OTCQB: ROOOF) ("Northstar" or the "Company") is pleased to announce that after positive discussions, we received a non-binding Letter of Interest ("LOI") from Export Development Canada ("EDC") for EDC to provide potential financial support, subject to the successful completion of its due diligence process, for the Company's first planned shingle reprocessing facility in the United States ("US Facility#1") and subject to a number of conditions and outcomes, potential funding support for an additional three Northstar processing facilities in the United States. Similar to the non-revolving secured debt facility outstanding with the Business Development Bank of Canada ("BDC") associated with the Company's Empower Calgary Facility, the LOI represents project financing where the security package, financial covenants and debt servicing requirements are directly attributable to the US Facility#1 itself. The LOI stipulates EDC to maintain a first ranking, or senior secured position, on the underlying assets with the ability to co-lend with other debt providers. EDC could extend credit up to C$12.5 million. Financial and reporting covenants, guarantees and pricing would apply and will be finalized as part of ongoing discussions. EDC due diligence will require, among other matters, sufficient comfort on the commercialization of the Empower Calgary Facility, which is nearing commissioning completion, completion support for US Facility#1 involving cost overrun protections, and equity contributions from one or more parties prior to any draws under an EDC debt facility. "While still early days, we are very encouraged by EDC's interest to potentially provide financial support for our growth aspirations in the United States," stated Aidan Mills, President & CEO. "The United States represents a significant market for Northstar and we continue to advance site selection, permitting and securing long-term supply agreements, for a number of US locations. These efforts are in line with our existing liquid asphalt off-take arrangements for the first four facilities in the United States with TAMKO Building Products LLC. Our international growth objectives align seamlessly with EDC's mandate and we look forward to a long and prosperous partnership." "The LOI from EDC could ultimately lead to a foundational funding vehicle for Northstar's US capital strategy," commented Greg Phaneuf, VP Corporate Development & CFO. "Northstar's business model lends itself to prudent leverage to materially reduce our project cost of capital, thereby enhancing returns for our shareholders. We look forward to working with EDC to crystallize funding terms as part of our larger growth capital initiatives." About Northstar Northstar is a Canadian waste to value technology company focused on the sustainable recovery and reprocessing of asphalt shingles. Northstar developed and owns a proprietary design process for taking discarded asphalt shingles, otherwise destined for already over-crowded landfills, and extracts the liquid asphalt for use in new hot mix asphalt shingle manufacturing and asphalt flat roof systems while also extracting aggregate and fiber for use in construction products and other industrial applications. Focused on the circular economy, Northstar plans to reprocess used or defective asphalt shingle waste back into its three primary components for reuse/resale with its first commercial scale up facility in Calgary, Alberta. As an emerging innovator in sustainable processing, Northstar's mission aims at leading the recovery and reprocessing of asphalt shingles in North America that would otherwise be sent to landfill addressing numerous stakeholder objectives. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on For further information about Northstar, please visit On Behalf of the Board of Directors,Aidan MillsPresident & CEO, Director Cautionary Statement on Forward-Looking Information Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. This press release may contain forward–looking information within the meaning of applicable securities legislation, which forward–looking information reflects the Company's current expectations regarding future events. Forward-looking statements are often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect", "aim", "objective" or similar expressions. Forward-looking statements in this press release include statements concerning: (i) Northstar's plans to reprocess used shingles into their component parts in the inaugural commercial facility in Calgary; (ii) EDC to potentially provide financial support for the Company's first US located facility in addition to a further three US located facilities, (iii) EDC to fund up to C$12.5 million on the first US located facility; (iv) efforts with respect US site selection, permitting and securing long-term supply agreements; (v) anticipated completion of the Empower Calgary Facility; (vi) Northstar's ability to become a leader in the recovery and reprocessing of asphalt shingles in North America; and (vii) future capital raising opportunities and commitments. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including: risks related to factors beyond the control of the Company; inability of the Company to execute on its business plans; changes in business plans and strategies of the Company; the Company may require additional financing which may not be obtainable or on favourable terms; risk inherent to any capital financing transactions; economic uncertainty; and the risks and uncertainties which are more fully described under the heading "Risk Factors" in the Company's annual and quarterly management's discussion and analysis and other filings with the Canadian securities regulatory authorities under the Company's profile on SEDAR+. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. The Company does not undertake any obligation to update such forward–looking information whether because of new information, future events or otherwise, except as expressly required by applicable law. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, expected or aimed. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. The Company does not intend, and does not assume any obligation, to update the forward-looking statements except as otherwise required by applicable law. View original content to download multimedia: SOURCE Northstar Clean Technologies Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store